BERLIN (dpa-AFX) - German drug maker Merck KGaA (MKGAY.PK) is considering a sale of its allergy business, known as Allergopharma, as it seeks to reduce debt following the $17 billion takeover of Sigma-Aldrich Corp., the Bloomberg reported, citing people with knowledge of the matter.
The process is at an early stage and Merck could still decide against a sale, the report said.
The report specified that the business may fetch about 600 million euros and could attract interest from drug companies and private-equity firms.
The Allergopharma business focuses on diagnosing allergies and treating them by training patients' immune systems to be less reactive to substances such as mold and pollen.
Copyright RTT News/dpa-AFX